Protocol Ledger

NCT03952585 · Phase II/III · ACTIVE NOT RECRUITING

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

Interventional Phase II/III clinical trial protocol NCT03952585 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-10-09 Enrollment: 384 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03952585
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)384 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03952585
Protocol FieldVerified Registry Value
NCT IdentifierNCT03952585
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment384 participants (ACTUAL)
Registered Start Date2019-10-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI